Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK

Objective: To evaluate the cost-effectiveness of solifenacin 5 mg/day versus other oral antimuscarinic agents used for overactive bladder (OAB) from a UK National Health Service (NHS) perspective. Study design: In a Markov model, hypothetical patients received solifenacin 5 mg/day or a comparator an...

Full description

Bibliographic Details
Main Authors: Zalmai Hakimi, Con Kelleher, Samuel Aballéa, Khaled Maman, Jameel Nazir, Colette Mankowski, Isaac Odeyemi
Format: Article
Language:English
Published: Taylor & Francis Group 2018-01-01
Series:Journal of Market Access & Health Policy
Subjects:
Cost utility
incremental cost-effectiveness ratio
Markov
quality-adjusted life year
mirabegron
muscarinic agents
Online Access:http://dx.doi.org/10.1080/20016689.2018.1438721

Internet

http://dx.doi.org/10.1080/20016689.2018.1438721

Similar Items